UK schizophrenia drug market is estimated to grow significantly at a CAGR of 2.7% during the forecast period. This growth is backed by a significant share of the population with behavioral health disorders, availability of the mental health workforce, government programs on mental illness and the growing awareness towards mental health in the country. Mental Health First Aid (MHFA) England is a social organization that offers expert guidance and training to support mental health. 1 in 4 people face mental health issues each year and responsible for 72 million working days lost and costs $45.5 billion each year as per the MHFA statistics 2019. 

Visit for Global Schizophrenia Drugs Market Report at: https://www.omrglobal.com/industry-reports/schizophrenia-drugs-market

Moreover, the significant cases of mental health disorders in UK armed forces further provide a significant share in the schizophrenia drugs market. As per MHFA in 2018-2019, around 4,214 or 2.7% of UK armed forces personnel were assessed with mental health disorders. Moreover, National Health Services (NHS) England spends $7.2 million per year on mental health services for ex-service personnel, in addition to the $12.7 billion spending on mental health for the general population, therefore, create significant market growth in the country.

UK schizophrenia drug market is classified on the basis of therapeutic class and treatment. Based on therapeutic class, the market is segmented into second-generation antipsychotics, third-generation antipsychotics, and other therapeutic classes. Among these therapeutic classes, the second-generation antipsychotics are majorly used in therapeutic classes for the treatment of schizophrenia. Based on treatment, the market is bifurcated into oral and injectables. The oral treatment solution dominates the market due to the presence of a large number of drug manufacturing companies in the country.

The companies which are contributing to the growth of the UK schizophrenia drugs market include Allergan PLC, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Co., AstraZeneca PLC, and Johnson & Johnson Services, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. 

Research Methodology

The market study of the UK schizophrenia drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation

1. UK Schizophrenia Drugs Market Research and Analysis by Therapeutic Class
2. UK Schizophrenia Drugs Market Research and Analysis by Treatment

The Report Covers

• Comprehensive research methodology of the UK schizophrenia drug market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the UK schizophrenia drug market.
• Insights about market determinants which are stimulating the UK schizophrenia drugs market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.